Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodies
- PMID: 36323338
- DOI: 10.1515/cclm-2022-0875
Preanalytical stability of SARS-CoV-2 anti-nucleocapsid antibodies
Abstract
Objectives: Anti-nucleocapsid (NC) antibodies are produced in response to SARS-CoV-2 infection. Therefore, they are well suited for the detection of a previous infection. Especially in the case of seroprevalence studies or during the evaluation of a novel in-vitro diagnostic test, samples have been stored at <-70 °C (short- and long-term) or 2-10 °C (short-term) before analysis. This study aimed to assess the impact of different storage conditions relevant to routine biobanking on anti-NC antibodies.
Methods: The preanalytical impact of short-term storage (84 [58-98] days) on <-70 °C and for 14 days at 2-10 °C was evaluated using samples from 111 donors of the MedUni Vienna Biobank. Long-term effects (443 [409-468] days) were assessed using 208 samples from Biobank Graz and 49 samples from Biobank Vienna. Anti-Nucleocapsid antibodies were measured employing electrochemiluminescence assays (Roche Anti-SARS-CoV-2).
Results: After short-term storage, the observed changes did not exceed the extent that could be explained by analytical variability. In contrast, results after long-term storage were approximately 20% higher and seemed to increase with storage duration. This effect was independent of the biobank from which the samples were obtained. Accordingly, the sensitivity increased from 92.6 to 95.3% (p=0.008). However, comparisons with data from Anti-Spike protein assays, where these deviations were not apparent, suggest that this deviation could also be explained by the analytical variability of the qualitative Anti-NC assay.
Conclusions: Results from anti-NC antibodies are stable during short-term storage at <-70 °C and 2-10 °C. After long-term storage, a slight increase in sensitivity could not be ruled out.
Keywords: SARS-CoV-2 antibodies; preanalytical phase; serology; stability; storage.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
References
-
- Aydillo, T, Rombauts, A, Stadlbauer, D, Aslam, S, Abelenda-Alonso, G, Escalera, A, et al.. Immunological imprinting of the antibody response in COVID-19 patients. Nat Commun 2021;12:3781. https://doi.org/10.1038/s41467-021-23977-1 . - DOI
-
- Niedrist, T, Drexler, C, Torreiter, PP, Matejka, J, Strahlhofer-Augsten, M, Kral, S, et al.. Longitudinal comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity in COVID-19 convalescent sera. Arch Pathol Lab Med 2022;146:538–46. https://doi.org/10.5858/arpa.2021-0604-sa . - DOI
-
- Perkmann, T, Koller, T, Perkmann-Nagele, N, Klausberger, M, Duerkop, M, Holzer, B, et al.. Spike protein antibodies mediate the apparent correlation between SARS-CoV-2 nucleocapsid antibodies and neutralization test results. Microbiol Spectr 2021;9:e0021821. https://doi.org/10.1128/spectrum.00218-21 . - DOI
-
- Perkmann, T, Perkmann-Nagele, N, Breyer, MK, Breyer-Kohansal, R, Burghuber, OC, Hartl, S, et al.. Side-by-side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity. Clin Chem 2020;66:1405–13. https://doi.org/10.1093/clinchem/hvaa198 . - DOI
-
- Huergo, LF, Paula, NM, Gonçalves, ACA, Kluge, CHS, Marins, P, Camargo, HSC, et al.. SARS-CoV-2 seroconversion in response to infection and vaccination: a time series local study in Brazil. Microbiol Spectr 2022;10:e0102622. https://doi.org/10.1128/spectrum.01026-22 . - DOI
MeSH terms
Substances
LinkOut - more resources
Medical